BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang S, Yuan B, Wang Y, Li M, Liu X, Cao J, Li C, Hu J. Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a meta-analysis. Int J Colorectal Dis 2021;36:117-30. [PMID: 32910207 DOI: 10.1007/s00384-020-03734-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Ibrahiem AT, Eladl E, Toraih EA, Fawzy MS, Abdelwahab K, Elnaghi K, Emarah Z, Shaalan AAM, Ehab Z, Soliman NA. Prognostic Value of BRAF, Programmed Cell Death 1 (PD1), and PD Ligand 1 (PDL1) Protein Expression in Colon Adenocarcinoma. Diagnostics (Basel) 2023;13. [PMID: 36673047 DOI: 10.3390/diagnostics13020237] [Reference Citation Analysis]
2 Campana LG, Mansoor W, Hill J, Macutkiewicz C, Curran F, Donnelly D, Hornung B, Charleston P, Bristow R, Lord GM, Valpione S. T-Cell Infiltration and Clonality May Identify Distinct Survival Groups in Colorectal Cancer: Development and Validation of a Prognostic Model Based on The Cancer Genome Atlas (TCGA) and Clinical Proteomic Tumor Analysis Consortium (CPTAC). Cancers (Basel) 2022;14. [PMID: 36497365 DOI: 10.3390/cancers14235883] [Reference Citation Analysis]
3 Zhang Y, Han L, Zhang Q, Liu Z, Niu H, Li L, Hu J, Shi X, Ding Z, Qian X. Exploring the expression and the prognosis of mismatch repair protein and PD-L1 in colorectal cancer.. [DOI: 10.21203/rs.3.rs-2287083/v1] [Reference Citation Analysis]
4 Hou W, Yi C, Zhu H. Predictive biomarkers of colon cancer immunotherapy: Present and future. Front Immunol 2022;13:1032314. [PMID: 36483562 DOI: 10.3389/fimmu.2022.1032314] [Reference Citation Analysis]
5 Hrudka J, Matěj R, Nikov A, Tomyak I, Fišerová H, Jelínková K, Waldauf P. Loss of SATB2 expression correlates with cytokeratin 7 and PD-L1 tumor cell positivity and aggressiveness in colorectal cancer. Sci Rep 2022;12:19152. [PMID: 36351995 DOI: 10.1038/s41598-022-22685-0] [Reference Citation Analysis]
6 Liang Z, Hu X, Hu H, Wang P, Cai J. Novel small 99mTc-labeled affibody molecular probe for PD-L1 receptor imaging. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1017737] [Reference Citation Analysis]
7 Xiao Z, Nie K, Han T, Cheng L, Zhang Z, Peng W, Shi D. Development and Validation of a TNF Family-Based Signature for Predicting Prognosis, Tumor Immune Characteristics, and Immunotherapy Response in Colorectal Cancer Patients. J Immunol Res 2021;2021:6439975. [PMID: 34541005 DOI: 10.1155/2021/6439975] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
8 Yang Y, Xia L, Wu Y, Zhou H, Chen X, Li H, Xu M, Qi Z, Wang Z, Sun H, Cheng X. Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN/VEGFR2 signaling axis in ovarian cancer. Cancer Commun (Lond) 2021;41:511-27. [PMID: 33939321 DOI: 10.1002/cac2.12157] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
9 Siraj AK, Parvathareddy SK, Annaiyappanaidu P, Haqawi W, Al-Rasheed M, AlManea HM, AlHussaini HF, Al-Dayel F, Al-Kuraya KS. PD-L1 Expression Is Associated with Deficient Mismatch Repair and Poor Prognosis in Middle Eastern Colorectal Cancers. J Pers Med 2021;11:73. [PMID: 33530623 DOI: 10.3390/jpm11020073] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]